Boceprevir Wins FDA Approval to Treat Hepatitis C

WASHINGTON (MedPage Today) — The FDA has approved the investigational drug boceprevir (Victrelis), in combination with peginterferon and ribavirin, to treat hepatitis C genotype 1, making it the first HCV protease inhibitor to reach market.

Post a Comment

Comments are closed.